Amgen Inc
I · Analyse IA
En bref
Amgen discovers, develops, manufactures, and delivers prescription medicines for serious illnesses including rheumatoid arthritis (Enbrel), high cholesterol (Repatha), osteoporosis (Prolia, Evenity), cancer (Blincyto, Kyprolis, Vectibix), and rare diseases like thyroid eye disease (Tepezza) [Yahoo Finance]. The company sells through doctors' offices, hospitals, dialysis centers, and pharmacies, primarily via pharmaceutical wholesalers [Yahoo Finance].
Amgen is the world's largest independent biotech company, developing and selling medicines for cancer, autoimmune diseases, osteoporosis, and rare conditions [Yahoo Finance]. The company generates $36,7B in annual revenue with strong margins, but faces serious safety concerns around its drug Tavneos, which has been linked to 20 deaths and 22 liver injuries in Japan [Seeking Alpha]. Recent leadership changes include the retirement of CFO Peter Griffith, who will be replaced by returning veteran Thomas Dittrich [Yahoo Finance].
Amgen is financially healthy with strong cash generation and reasonable leverage, earning a 7,4/10 health score [Sentinellis calculation].
Score Sentinellis
7,4/10
Préoccupations modérées
Capitalisation boursière
$178,6B
Chiffre d'affaires (12 mois)
$36,7B
Explications
Comment nous lisons ces chiffres
Guides en langage clair · sans compte
ROIC vs WACC Explained: How to Tell If a Company Actually Creates Value
What ROIC and WACC are, how to compute both, and why the spread between them is the single most important number in fundamental investing.
LirePiotroski F-Score Explained: A 9-Point Financial Health Check (with a Live Apple Example)
What the Piotroski F-Score is, how to calculate all 9 criteria, and how to read the result. Plain English, with a real Apple walkthrough.
LireAltman Z-Score Explained: Predicting Bankruptcy in 5 Minutes (with Real Examples)
What the Altman Z-Score is, the exact formula, how to read the result, and which version to use for manufacturers vs tech vs private companies.
LireII · Actualités récentes
Ce qui a fait bouger le cours
6 articles · classés par pertinence
- Macro2026-05-19
AMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITH
Yahoo Finance
- Macro2026-05-18
Amgen (AMGN) Gets Price Target Cut at Piper Sandler Despite Long-Term Growth Optimism
Yahoo Finance
- Macro2026-05-18
Middle East and Africa Wearable Injectors Market Trends and Forecast Report 2026-2035 Featuring Amgen, BD, Biocon, Gerresheimer, Insulet, J&J, Medtronic, Roche, West Pharmaceutical, Ypsomed
Yahoo Finance
- Macro2026-05-18
Amgen Japanese Partner Urges Caution On Tavneos Use
Yahoo Finance
- Macro2026-05-15
Is It Time To Reassess Amgen (AMGN) After Strong Multi Year Share Price Gains
Simply Wall St
- Macro2026-05-15
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Zacks
Premium · gratuit avec tout compte
Tavneos faces serious safety scrutiny in Japan after being linked to 20 deaths and 22 liver injuries, which could lead to restricted use, regulatory action, or lawsuits in other markets where Amgen sells the drug [Seeking Alpha]
Risques
4
Opportunités
5
Signaux d'alerte
3
Direction
10
11 autres constats dans le rapport complet — gratuit avec tout compte.
Débloquer l'analyse complète de Amgen Inc
Créez un compte gratuit pour accéder au rapport complet généré par IA, avec les sources citées dans le texte.
- 4 risques, 5 opportunités et 3 signaux d'alerte — chacun avec sa source
- Plus de 100 indicateurs financiers avec graphiques et comparaisons
- Résumés d'actualités complets avec liens vers les sources
- Équipe dirigeante et rémunération
III · Entreprises similaires
À lire également
Même secteur · Santé — ou santé financière comparable
L'ajouter à votre liste ?